89Zr-labeled Pembrolizumab in Patients With Non-small-cell Lung Cancer
Status:
Unknown status
Trial end date:
2019-12-01
Target enrollment:
Participant gender:
Summary
After a screening phase of up to 42 days, eligible subjects will undergo two whole body
immuno-PET scans with a non-therapeutic tracer dose (2 mg) of 89Zr-pembrolizumab; one with
and one without a preceding "cold" therapeutic dose of pembrolizumab. For the first 3
patients, PET scans will be obtained at 1, 72 and 120 hours post tracer injection to
determine the optimal scan time point and to perform biodistribution measurements and
dosimetry. All subsequent patients receive only 1 PET scan post-injection (i.e. two PET
scans). The optimal time point is expected to be at day 5 post-injection. Pembrolizumab
treatment will continue every three weeks until two years of therapy have been administered,
disease progression, or unacceptable adverse event(s).